Tocilizumab in Severe COVID-19 Disease: Does Timing Matters?

被引：0
|
作者：
Cherrez-Ojeda, I. [1 ]
Vanegas, E. [2 ]
Felix, M. [2 ]
Tovar, M. [3 ]
Bravo, P. [3 ]
Pena, J. [3 ]
Jauregui, J. [3 ]
Silva, D. [3 ]
Bolona, E. [3 ]
机构：
[1] Respiralab, Guayaquil, Ecuador
[2] Univ Espiritu Santo, Samborondon, Ecuador
[3] Clin Guayaquil, Guayaquil, Ecuador
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2021年 / 203卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2653
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Predictors of the Outcomes Following the Tocilizumab Treatment for Severe COVID-19
    Singla, Karan
    Puri, Goverdhan D.
    Niyogi, Subhrashis Guha
    Mahajan, Varun
    Kajal, Kamal
    Bhalla, Ashish
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (08)
  • [32] Authors’ Reply to: Tocilizumab, Adipokines and Severe Complications of COVID-19
    Bin Liu
    Zhigang Qi
    Clinical Drug Investigation, 2020, 40 : 893 - 895
  • [33] Tocilizumab in patients with severe COVID-19: a retrospective cohort study
    Guaraldi, Giovanni
    Meschiari, Marianna
    Cozzi-Lepri, Alessandro
    Milic, Jovana
    Tonelli, Roberto
    Menozzi, Marianna
    Franceschini, Erica
    Cuomo, Gianluca
    Orlando, Gabriella
    Borghi, Vanni
    Santoro, Antonella
    Di Gaetano, Margherita
    Puzzolante, Cinzia
    Carli, Federica
    Bedini, Andrea
    Corradi, Luca
    Fantini, Riccardo
    Castaniere, Ivana
    Tabbi, Luca
    Girardis, Massimo
    Tedeschi, Sara
    Giannella, Maddalena
    Bartoletti, Michele
    Pascale, Renato
    Dolci, Giovanni
    Brugioni, Lucio
    Pietrangelo, Antonello
    Cossarizza, Andrea
    Pea, Federico
    Clini, Enrico
    Salvarani, Carlo
    Massari, Marco
    Viale, Pier Luigi
    Mussini, Cristina
    LANCET RHEUMATOLOGY, 2020, 2 (08): : E474 - E484
  • [34] Tocilizumab in HIV patient with severe COVID-19: case report
    Bertozzi, Pedro Vieira
    Vicente, Amanda de Oliveira
    Pereira, Amanda Siqueira
    Espinha de Sant'Ana, Joao Pedro
    Cabrera Mano, Rafaela Braga
    Jorge, Luciana Souza
    da Silva Sardenberg, Rodrigo Afonso
    AIDS RESEARCH AND THERAPY, 2021, 18 (01):
  • [35] Predictors of Mortality in Tocilizumab-Treated Severe COVID-19
    Pagkratis, Konstantinos
    Chrysikos, Serafeim
    Antonakis, Emmanouil
    Pandi, Aggeliki
    Kosti, Chrysavgi Nikolaou
    Markatis, Eleftherios
    Hillas, Georgios
    Digalaki, Antonia
    Koukidou, Sofia
    Chaini, Eleftheria
    Afthinos, Andreas
    Dimakou, Katerina
    Papanikolaou, Ilias C.
    VACCINES, 2022, 10 (06)
  • [36] Why tocilizumab could be an effective treatment for severe COVID-19?
    Fu, Binqing
    Xu, Xiaoling
    Wei, Haiming
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
  • [37] Tocilizumab for Severe and Critical COVID-19 Pneumonia in Queens, NYC
    Salama, Carlos
    Kaplan-Lewis, Emma
    Durrance, Richard
    Wong, Linda
    Arumugam, Vasanthi
    Fabbri, Marilyn
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 2021, 29 (04) : E215 - E220
  • [38] TOCILIZUMAB USE IN SEVERE COVID-19: A SINGLE CENTER EXPERIENCE
    Poon, Joseph
    Ho, Kam Sing
    Herrera, Yasmin
    Jean, Raymonde
    CHEST, 2020, 158 (04) : 687A - 687A
  • [39] Authors' Reply to: Tocilizumab, Adipokines and Severe Complications of COVID-19
    Liu, Bin
    Qi, Zhigang
    CLINICAL DRUG INVESTIGATION, 2020, 40 (09) : 893 - 895
  • [40] Tocilizumab-A beacon of hope in the management of severe COVID-19?
    Christou, Sabina
    Mohamed, Siham
    Tsigarides, Jordan
    JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (02) : 675 - 677
12345